1-4 of 4
Konstantin H. Dragnev
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials?

Sai Yendamuri, Konstantin H. Dragnev
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2024) 17 (9): 399–400.
https://doi.org/10.1158/1940-6207.CAPR-24-0234
Published: 04 September 2024
View article titled, Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials?
Open the PDF for Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials? in another window
Journal Articles

Primary Prevention and Interception Studies in RAS-Mutated Tumor Models Employing Small Molecules or Vaccines

Konstantin H. Dragnev, Ronald A. Lubet, Mark Steven Miller, Shizuko Sei, Jennifer T. Fox, Ming You
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2023) 16 (10): 549–560.
https://doi.org/10.1158/1940-6207.CAPR-23-0027
Published: 02 October 2023
View article titled, Primary Prevention and Interception Studies in RAS-Mutated Tumor Models Employing Small Molecules or Vaccines
Open the PDF for Primary Prevention and Interception Studies in RAS-Mutated Tumor Models Employing Small Molecules or Vaccines in another window
Includes: Supplementary data
Journal Articles

Abstract CN05-03: Cooperation between a rexinoid and EGFR-TKI for lung cancer prevention via Cyclin D1 destabilization

Konstantin H. Dragnev, Vincent Memoli, Sarah J. Freemantle, Samuel Waxman, Ethan Dmitrovsky
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2015) 8 (10_Supplement): CN05-03.
https://doi.org/10.1158/1940-6215.PREV-14-CN05-03
Published: 02 October 2015
View article titled, Abstract CN05-03: Cooperation between a rexinoid and EGFR-TKI for lung cancer prevention via Cyclin D1 destabilization
Journal Articles

Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models

Konstantin H. Dragnev, Tian Ma, Jobin Cyrus, Fabrizio Galimberti, Vincent Memoli, Alexander M. Busch, Gregory J. Tsongalis, Marc Seltzer, David Johnstone, Cherie P. Erkmen, William Nugent, James R. Rigas, Xi Liu, Sarah J. Freemantle, Jonathan M. Kurie, Samuel Waxman, Ethan Dmitrovsky
Journal: Cancer Prevention Research
Cancer Prev Res (Phila) (2011) 4 (6): 818–828.
https://doi.org/10.1158/1940-6207.CAPR-10-0376
Published: 01 June 2011
View article titled, Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of <em>KRAS</em> Mutations in Two Clinical Trials and Transgenic Models
Open the PDF for Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of <em>KRAS</em> Mutations in Two Clinical Trials and Transgenic Models in another window
Includes: Supplementary data